BEST UNLIMITED TURBO LONG CERTIFICATE - CRISPR THERAPEUTICS Stock

Certificat

EF56S

DE000SQ3BKL7

Real-time Euronext Paris 07:04:31 2024-05-21 EDT
3.646 EUR +0.39% Intraday chart for BEST UNLIMITED TURBO LONG CERTIFICATE - CRISPR THERAPEUTICS
Current month+7.52%
1 month+1.25%
Date Price Change
24-05-21 3.646 +0.39%
24-05-20 3.632 -0.38%
24-05-17 3.646 +0.28%
24-05-16 3.636 -4.64%
24-05-15 3.813 +0.95%

Real-time Euronext Paris

Last update May 21, 2024 at 07:04 am

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying CRISPR THERAPEUTICS AG
IssuerLogo Issuer Société Générale Société Générale
EF56S
ISINDE000SQ3BKL7
Date issued 2022-10-24
Strike 36.74 $
Maturity Unlimited
Parity 5 : 1
Emission price 4.11
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 10.27
Lowest since issue 0.788
Spread 0.286
Spread %7.55%

Company Profile

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Sector
-
More about the company

Ratings for CRISPR Therapeutics AG

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: CRISPR Therapeutics AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
55.47 USD
Average target price
86.78 USD
Spread / Average Target
+56.45%
Consensus
  1. Stock Market
  2. Certificates
  3. EF56S Certificat
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW